(Q37877409)

24 August 2017

1 reference

title

Anti-angiogenic therapy in glioma (English)

1 reference

24 August 2017

main subject

angiogenesis inhibitor

1 reference

Nicholas Butowski

1

1 reference

24 August 2017

publication date

1 May 2011

1 reference

Clinical and Translational Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

294-300

1 reference

Tumor angiogenesis: therapeutic implications

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Maximizing the potential of bevacizumab in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Molecular targeted therapies and chemotherapy in malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Analogs of staurosporine: potential anticancer drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Protein kinase C targeting in antineoplastic treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Inhibition of protein kinase C--do we, can we, and should we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Synergistic antiglioma activity of radiotherapy and enzastaurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

A phase I trial of enzastaurin in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Thalidomide in multiple myeloma: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Thalidomide as an anti-angiogenic agent in relapsed gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Inhibition of angiogenesis and invasion in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Morphologic instability and cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Downstream-of-FGFR is a fibroblast growth factor-specific scaffolding protein and recruits Corkscrew upon receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Brain tumor imaging in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Response and progression in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Response criteria for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0657-2

21 January 2018

1 reference

12 December 2020

Antiangiogenic therapy for cancer: an update

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.

1 reference

12 December 2020

A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors.

1 reference

12 December 2020

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

1 reference

12 December 2020

Thalidomide: 40 years on.

1 reference

12 December 2020

Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.

1 reference

12 December 2020

Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms

1 reference

12 December 2020

[The revival of thalidomide: an old drug with new indications]

1 reference

12 December 2020

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms

1 reference

12 December 2020

10.1007/S12094-011-0657-2

Identifiers

DOI

1 reference

24 August 2017

1 reference